Answers are grounded in this paper and cite their sources.
This large autoantibody screening reveals links between immune responses and adverse events in melanoma patients, suggesting personalized treatment approaches.
This study, to our knowledge, is the largest pretreatment autoantibody screen in melanoma immunotherapy, demonstrates that serum autoantibody profiles can stratify patients at risk for irAEs and ir-colitis. The identified signatures connect tumor-related and immunity-related antigens, stress-response pathways, and autoimmune mechanisms. Pretreatment autoantibody profiling offers a promising biomarker-driven approach for individualizing risk assessment, improving patient selection, and guiding early intervention strategies to enhance the safety of immune checkpoint blockade in melanoma. Beyond toxicity prediction, our findings also suggest that specific autoantibodies may reflect underlying immune activation states linked to therapeutic response.
No takes yet. Share an insight, caveat, or question.
Reschke et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: